Oxford University Begins Phase 3 COVID-19 Vaccine Trial in Brazil

The University of Oxford has begun a phase 3 trial of its COVID-19 vaccine in Brazil, making it the first phase 3 trial of its kind in Latin America.

The trial, in partnership with AstraZeneca, will enroll 5,000 volunteers. The vaccine candidate, AZD1222,  is also in phase 2/3 trials in the UK and South Africa.

Brazil’s Ministry of Health has signed an agreement with AstraZeneca for local production of the vaccine.